Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01647958 · ClinicalTrials.gov registry record · NA
The EndoGastric Solutions TEMPO Trial
A NA study, sponsored by EndoGastric Solutions.
- Completed
- Registry status
- NA
- Development phase
- 65
- Enrollment target
NCT01647958 is a NA study that has completed, run by EndoGastric Solutions. The registered enrollment target is 65 participants.
The verdict
NCT01647958, a NA study, has completed, sponsored by EndoGastric Solutions.
- COMPLETED
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of Transoral Incisionless Fundoplication (TIF) performed with EsophyX as compared to proton pump inhibitor (PPI) therapy for the treatment of chronic Gastroesophageal Reflux Disease (GERD) patients with refractory symptoms on Proton Pump Inhibitors (PPIs).
Interventions
- DRUG PPI
- DEVICE EsophyX System with SerosaFuse fasteners
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2012-06-01 |
| Est. Completion | 2017-12-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01647958
The ClinicalTrials.gov registry entry for NCT01647958 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EndoGastric Solutions, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PPI is the first listed.
NCT01647958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01647958 about?
NCT01647958 is a clinical study titled "The EndoGastric Solutions TEMPO Trial". The purpose of this study is to assess the efficacy and safety of Transoral Incisionless Fundoplication (TIF) performed with EsophyX as compared to proton pump inhibitor (PPI) therapy for the treatment of chronic Gastroesophageal Reflux Disease (GERD) patients with refractory symptoms on Proton Pump...
What is the current status of trial NCT01647958?
This trial is currently completed. It is a NA study. The enrollment target is 65 participants. The study started on 2012-06-01. Estimated completion is 2017-12-01.
What interventions are being tested in trial NCT01647958?
The interventions under investigation include: PPI (DRUG), EsophyX System with SerosaFuse fasteners (DEVICE).
Who is sponsoring clinical trial NCT01647958?
This trial is sponsored by EndoGastric Solutions, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.